ASCO 2020：11项中国研究入选口头年度报告，17项Poster年度报告

受全球新冠疫情因素，顺延于5年初29日~6年初2日在辛辛那提闭幕的美国针灸学会（ASCO）年会今年将首次以线上多种形式举办，这是目前最大规模的线上庆典。直到现在，大会的简短答案列入，共五103个sessions，之中国人共五有11项归纳表现出色口头报告，17项表现出色Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

酮类替尼或拉帕替尼加卡培他平野用于HER2+移往病态乳腺乳癌（PHOEBE）：一项III期随机实验。

大舞台：移往病态乳腺乳癌

著者：之中国人医学科学院病房徐兵河研究员、马飞研究员，浙江大学另设病房胡夕春研究员等

简短号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴病态乳腺乳癌标准疗法后卡培他平野延续节拍肌肉注射的III期实验（SYSUCC-001）。

大舞台：乳腺乳癌—全局/区域/专门设计疗法

著者：之中山大学卫生保健外围王树森研究员等

简短号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移往病态脑的表型特点来预报脑脊液之中周而复始DNA测定的概率: 新机器对抗从前对手

大舞台：新机器解决从前问题

著者：蔡美芹 蔡科克等

简短号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对比索拉非尼作为早期肺细胞核乳癌的中卫疗法：一项闭馆标签、随机、多外围II/III期实验。

大舞台：小肠肠道乳癌—小肠胃、十二指肠和肺胆

著者：南京大学华西病房毕锋研究员、解放军新华病房秦叔逵研究员等

简短号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

之中国人早期小肠乳癌病人阿帕替尼双线疗法：一项随机、安慰剂对应、双盲III期归纳

大舞台：小肠肠道乳癌—小肠胃、十二指肠和肺胆

著者：解放军新华病房秦叔逵研究员、南京大学华西病房蔡秋研究员等

简短号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

早期发作病态卵巢乳癌二次细胞核减灭术的一项随机III期实验：SOC1 / SGOG-OV2。

不定期：内科肺炎

著者：浙江大学另设之中山病房臧荣余研究员等

简短：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治病态卵巢切除术后专门设计疗法之中的序贯放肌肉注射对比实际上放疗或并行放肌肉注射（STARS归纳）：一项随机、对应、闭馆标签的III期实验。

大会：内科肺炎

著者：之中山大学卫生保健外围白云研究员、刘继红研究员等

简短号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：专门设计吉非替尼对比肌肉注射用于可切除的EGFR等位基因的N1-N2期NSCLC-随机III期针灸实验的最终各个方面生存归纳。

不定期：小肠乳癌—非小细胞核全局-区域/小细胞核/其他胸部

著者：珠海市祖国病房吴一龙研究员等

简短号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR等位基因寡移往非小细胞核小肠乳癌病人中卫酪氨酸蛋白激酶抑制剂倡议或不倡议积极前线全局放疗：III期闭馆标签针灸随机实验（SINDAS）的之中期结果（NCT02893332）。

不定期：小肠乳癌-非小细胞核移往

著者：绵阳市祖国病房曾铭研究员等

简短：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序病态幸存者-1（PD-1）的人源化IgG4化学合成倡议阿昔替尼用于移往病态黏膜脑瘤病人的Ib期归纳的总生存期和生物标志物归纳。

不定期：脑瘤/皮肤乳癌

著者：北京大学病房郭军、盛锡楠研究员等

简短：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的稳定病态和结果：通用CAR-T细胞核首次生理实验疗法发作/难治病态T细胞核急病态细胞会核肺炎（r/r T-ALL）的稳定病态和。大会：共五同开发之中的疗法技术-免疫疗法。著者：王后林等简短：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利肌肉注射在早期胃鳞状细胞核乳癌病人之中的应用：一项随机的闭馆标签II期实验（ORIENT-2）。大会：小肠肠道乳癌-小肠胃乳癌、十二指肠乳癌和肺胆道乳癌著者：徐建明研究员等简短：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异病态CAR-T细胞核对髓母细胞核瘤的造成危害病态疗法大会：之中枢神经系统著者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东简短：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在早期错配修复缺陷病人之中的应用大会：共五同开发之中的疗法学-免疫疗法著者：沈琳研究员等简短：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨髓CD7-CART疗法发作/难治病态ACUTE细胞会核肺炎/淋巴瘤的首例生理针灸实验大会: 共五同开发病态疗法学-免疫疗法著者简介：张明志，南部县等简短：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议应用于早期单一瘤病人的Ib期归纳大会：发展病态疗法学便是分子小分子药物和生物学著者：龚继芳，沈琳研究员等简短：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议紫杉醇和nedaplatin疗法发作病态或移往病态胃鳞状细胞核乳癌（ESCC）病人的II期归纳。大会：小肠肠道乳癌-小肠胃、十二指肠和肺胆道乳癌的归纳著者：王志超强，蔡玉红，王德申，王凤华，任超，谭琼 王志超强、蔡玉红、王德深、王凤华、任超、谭琼简短：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.大会：小肠肠道乳癌-小肠胃乳癌、十二指肠乳癌和肺胆管乳癌的双线疗法著者：宋艳等简短：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种尿液外体网状RNA分类器用于初始前列腺时测定高等级乳癌的尿液外体网状RNA分类器：一项多外围的回顾病态归纳大会：心脏生殖细胞肺炎便是-乳癌、帕金森氏症和乳癌著者简介：Liaoyuan Li等简短：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 全局早期宫颈乳癌并作肌肉注射后的专门设计肌肉注射大会: 内科肺炎著者简介： 蔡珉珉等简短：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼疗法甲状腺髓病态乳癌的相关病态：基于ALTER01031实验的归纳。会话里：肩部著者：天津病房得意研究员简短：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼疗法后病人结局的因素: ALTER01031的亚组归纳大会：肩部著者：天津病房得意研究员简短：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA归纳预报I-IIIA期非小细胞核小肠乳癌（NSCLC）病人术后发作: GASTO1035和GASTO1018的结果大会：小肠乳癌-非小细胞核全局-区域病态/小细胞核/小细胞核/其他胸科肺炎著者：Si-Yu Wang等简短：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞核小肠乳癌（NSCLC）之中EGFR酪氨酸蛋白激酶抑制剂的新型青霉素机制大会:小肠乳癌-非小细胞核移往病态小肠乳癌著者简介：赵昕，金玲玲，满宇，欧名妓，金兰，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧名妓、金兰、薛武、杨绍、范敏简短：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1实验之中早期脑瘤总生存的替代往南大会：脑瘤/皮肤乳癌著者：聂润聪，袁书超强，蔡元芳，陈英波，周志伟 聂润聪、袁书超强、蔡元芳、陈英波、周志伟简短：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼疗法发作或移往病态原发病态恶病态骨病人的II期归纳大会： 病变著者：唐丽娜，牛晓辉，王稼祥，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶简短：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在早期病变病人多线疗法之中的稳定病态和。大会：病变著者：姚伟涛，王家超强，张瑞，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、王家超强、张瑞、王鑫、杜鑫辉、田志超、牛晓英简短：11526宣传品：414